Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers

Cancer Epidemiology Centre, Victorian Cancer Registry, Carlton, Victoria, Australia.
Journal of the National Cancer Institute (Impact Factor: 12.58). 12/2009; 102(3):193-201. DOI: 10.1093/jnci/djp473
Source: PubMed


Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.
We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment.
For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as follows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% (95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% (95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial cancer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch syndrome (HR = 6.0, 95% CI = 3.4 to 10.7).
We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation carriers.

Download full-text


Available from: Graham G Giles,
  • Source
    • "Thirty-six percent had mutations in MSH6 and 39% in MSH2. MSH6 mutation carriers are less likely to meet Amsterdam II criteria [33] and have a lower risk of colorectal cancer (10-22% cumulative risk by 70 years of age) and of other LS-related cancers [34,35]. As the Amsterdam II criteria have a reported sensitivity of 60-80% for colorectal cancer [36], but of only 20-30% in consecutive endometrial cancers [11,30], it is likely that our selection criteria have missed a number of LS families, especially those caused by MSH6 mutations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Uterine cancer (UC) represents 5.1% of all female malignancies in Sweden. Accumulation of UC in families occurs in around 5% of cases. We wanted to identify any familial association between UC and other selected cancers and to study the frequency of Lynch,Cowden and cancer syndromes among consecutive UC patients in Sweden. 481 UC patients were included. Information on the cancer diagnoses of their relatives (first- (FDRs) and second-degree (SDRs) relatives and first cousins) was obtained. The relative frequencies of different cancers among relatives were compared to those in the Swedish general cancer population in 1970 and 2010. Families that fulfilled the criteria for hereditary cancer syndromes were tested for mutations in the causative genes. Families with at least one case of UC in addition to the index patient were compared to families with no additional cases to investigate possible characteristics of putative hereditary cancer syndromes. There was an increased prevalence of UC in our study population compared to the Swedish general cancer population in 1970 and 2010 (6% vs. 4% and 3%, respectively). Seven families had Lynch Syndrome according to the Amsterdam II criteria. No families fulfilled the criteria for Cowden syndrome. In total 13% of index patients had at least one relative with UC and these families tended to have more cases of early onset cancer among family members. In addition, 16% of index patients were diagnosed with at least one other cancer. No families fulfilled the criteria for Cowden syndrome. We showed a familial clustering of UC among relatives of our index patients. Of the seven families with mutation-verified Lynch Syndrome, only one had been previously diagnosed, highlighting the need to increase gynecologists’ awareness of the importance of taking family history. Our data on multiple cancers and young age of onset in families with uterine cancer is compatible with the existence of additional hereditary uterine cancer syndromes.
    Hereditary Cancer in Clinical Practice 05/2014; 12(1):14. DOI:10.1186/1897-4287-12-14 · 1.47 Impact Factor
  • Source
    • "Tumors in MSH6 mutation carriers frequently show no or low MSI and the observed instability is generally restricted to mononucleotide markers [5–7]. When compared to MLH1 and MSH2 mutation carriers, the age of onset is generally later for MSH6 mutations carriers (approximately 10 years) and they have a lower risk for developing CRC [2,3]. There are reports of increased frequency of endometrial cancer in MSH6 mutation carriers versus MSH2 mutation carriers [8]; however, two large studies found no difference [2] or even a decreased [3] endometrial cancer incidence in patients carrying a mutation in MSH6. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lynch syndrome confers an increased risk to various types of cancer, in particular early onset colorectal and endometrial cancer. Mutations in mismatch repair (MMR) genes underlie Lynch syndrome, with the majority of mutations found in MLH1 and MSH2. Mutations in MSH6 have also been found but these do not always cause a clear cancer predisposition phenotype and MSH6-defective tumors often do not show the standard characteristics of MMR deficiency, such as microsatellite instability. In particular, the consequences of MSH6 missense mutations are challenging to predict, which further complicates genetic counseling. We have previously developed a method for functional characterization of MSH2 missense mutations of unknown significance. This method is based on endogenous gene modification in mouse embryonic stem cells using oligonucleotide-directed gene targeting, followed by a series of functional assays addressing the MMR functions. Here we have adapted this method for the characterization of MSH6 missense mutations. We recreated three MSH6 variants found in suspected Lynch syndrome families, MSH6-P1087R, MSH6-R1095H and MSH6-L1354Q, and found all three to behave like wild type MSH6. Thus, despite suspicion for pathogenicity from clinical observations, our approach indicates these variants are not disease causing. This has important implications for counseling of mutation carriers.
    PLoS ONE 09/2013; 8(9):e74766. DOI:10.1371/journal.pone.0074766 · 3.23 Impact Factor
  • Source
    • "Germline mutations in one of the mismatch repair genes (MLH1, MSH2, MSH6, PMS2) predispose people to colorectal cancer (CRC), endometrial cancer and some other cancers known as Lynch syndrome (Lynch and Chapelle 2003). Carriers of mutations in these genes have an approximate 30–60 % lifetime risk (to age 70 years) of CRC and 30–50 % lifetime risk of endometrial cancer depending on age and gender of carriers and the type of gene that is mutated (Baglietto et al. 2010; Bonadona et al. 2011; Senter et al. 2008). The only way to determine if unaffected people in families with a mismatch repair gene mutation have or have not inherited that mutation is genetic testing. "
    [Show abstract] [Hide abstract]
    ABSTRACT: People carrying germline mutations in mismatch repair genes are at high risk of colorectal cancer (CRC), yet about half of people from mutation-carrying families decline genetic counselling and/or testing to identify mutation status. We studied the association of quantitative measures of risk perception, risk prediction and self-reported screening colonoscopy in this elusive yet high-risk group. The sample of 26 participants (mean age 43.1 years, 14 women) in the Australasian Colorectal Cancer Family Registry were relatives of mutation carriers; had not been diagnosed with any cancer at the time of recruitment and had declined an invitation to attend genetic counselling and/or testing. A structured elicitation protocol captured perceived CRC risk over the next 10 years. Self-reported colonoscopy screening was elicited during a 45-minute semi-structured interview. Predicted 10-year CRC risk based on age, gender, known mutation status and family history was calculated using "MMRpro." Mean perceived 10-year risk of CRC was 31 % [95 % CI 21, 40], compared with mean predicted risk of 4 % [2, 7] (p < 0.001); this was independent of age and sex (p = 0.9). Among those reporting any medical advice and any screening colonoscopy (n = 18), those with higher risk perception had less frequent colonoscopy (Pearson's r = 0.49 [0.02, 0.79]). People who decline genetic testing for CRC susceptibility mutations perceive themselves to be at substantially higher risk than they really are. Those with high perceived risk do not undertake screening colonoscopy more often than those who perceive themselves to be at average risk.
    Journal of Genetic Counseling 06/2013; 23(1). DOI:10.1007/s10897-013-9614-2 · 2.24 Impact Factor
Show more